Global Rare Disease Drug Global Market Insights (2021 to 2026) - Key Analysis and Forecasts

News provided by

Dec 16, 2021, 14:45 ET

DUBLIN, Dec. 16, 2021 /PRNewswire/ -- The "Rare Disease Drug Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.

This report describes the global market size of Rare Disease Drug from 2016 to 2020 and its CAGR from 2016 to 2020, and also forecasts its market size to the end of 2026 and its CAGR from 2021 to 2026.

For the geography segment, regional supply, demand, major players, price is presented from 2016 to 2026.

This report covers the following regions:

North America
South America
Asia & Pacific
Europe
MEA

The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

For the competitor segment, the report includes global key players of Rare Disease Drug as well as some small players.

The information for each competitor includes:

Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share

Applications Segment:

Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others

Companies Covered:

Novartis AG
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Sanofi S.A.
Alexion Pharmaceuticals Inc.
Eli Lilly and Company
Novo Nordisk A/S
AstraZeneca

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method

Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users

Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
5.6 Covid-19 Impact

Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Rare Disease Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users

Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics

Chapter 8 Trading Analysis
8.1 Export of Rare Disease Drug by Region
8.2 Import of Rare Disease Drug by Region
8.3 Balance of Trade

Chapter 9 Historical and Forecast Rare Disease Drug Market in North America (2016-2026)
9.1 Rare Disease Drug Market Size
9.2 Rare Disease Drug Demand by End Use
9.3 Competition by Players/Suppliers
9.4 Type Segmentation and Price
9.5 Key Countries Analysis
9.5.1 United States
9.5.2 Canada
9.5.3 Mexico

Chapter 10 Historical and Forecast Rare Disease Drug Market in South America (2016-2026)
10.1 Rare Disease Drug Market Size
10.2 Rare Disease Drug Demand by End Use
10.3 Competition by Players/Suppliers
10.4 Type Segmentation and Price
10.5 Key Countries Analysis
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Chile
10.5.4 Peru

Chapter 11 Historical and Forecast Rare Disease Drug Market in Asia & Pacific (2016-2026)
11.1 Rare Disease Drug Market Size
11.2 Rare Disease Drug Demand by End Use
11.3 Competition by Players/Suppliers
11.4 Type Segmentation and Price
11.5 Key Countries Analysis
11.5.1 China
11.5.2 India
11.5.3 Japan
11.5.4 South Korea
11.5.5 Southeast Asia
11.5.6 Australia

Chapter 12 Historical and Forecast Rare Disease Drug Market in Europe (2016-2026)
12.1 Rare Disease Drug Market Size
12.2 Rare Disease Drug Demand by End Use
12.3 Competition by Players/Suppliers
12.4 Type Segmentation and Price
12.5 Key Countries Analysis
12.5.1 Germany
12.5.2 France
12.5.3 United Kingdom
12.5.4 Italy
12.5.5 Spain
12.5.6 Belgium
12.5.7 Netherlands
12.5.8 Austria
12.5.9 Poland
12.5.10 Russia

Chapter 13 Historical and Forecast Rare Disease Drug Market in MEA (2016-2026)
13.1 Rare Disease Drug Market Size
13.2 Rare Disease Drug Demand by End Use
13.3 Competition by Players/Suppliers
13.4 Type Segmentation and Price
13.5 Key Countries Analysis
13.5.1 Egypt
13.5.2 Israel
13.5.3 South Africa
13.5.4 Gulf Cooperation Council Countries
13.5.5 Turkey

Chapter 14 Summary For Global Rare Disease Drug Market (2016-2021)
14.1 Rare Disease Drug Market Size
14.2 Rare Disease Drug Demand by End Use
14.3 Competition by Players/Suppliers
14.4 Type Segmentation and Price

Chapter 15 Global Rare Disease Drug Market Forecast (2021-2026)
15.1 Rare Disease Drug Market Size Forecast
15.2 Rare Disease Drug Demand Forecast
15.3 Competition by Players/Suppliers
15.4 Type Segmentation and Price Forecast

Chapter 16 Analysis of Global Key Vendors
16.1 Novartis AG
16.1.1 Company Profile
16.1.2 Main Business and Rare Disease Drug Information
16.1.3 SWOT Analysis of Novartis AG
16.1.4 Novartis AG Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.2 Bristol-Myers Squibb Company
16.2.1 Company Profile
16.2.2 Main Business and Rare Disease Drug Information
16.2.3 SWOT Analysis of Bristol-Myers Squibb Company
16.2.4 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.3 Celgene Corporation
16.3.1 Company Profile
16.3.2 Main Business and Rare Disease Drug Information
16.3.3 SWOT Analysis of Celgene Corporation
16.3.4 Celgene Corporation Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.4 F. Hoffmann-La Roche Ltd.
16.4.1 Company Profile
16.4.2 Main Business and Rare Disease Drug Information
16.4.3 SWOT Analysis of F. Hoffmann-La Roche Ltd.
16.4.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.5 Pfizer Inc.
16.5.1 Company Profile
16.5.2 Main Business and Rare Disease Drug Information
16.5.3 SWOT Analysis of Pfizer Inc.
16.5.4 Pfizer Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.6 Sanofi S.A.
16.6.1 Company Profile
16.6.2 Main Business and Rare Disease Drug Information
16.6.3 SWOT Analysis of Sanofi S.A.
16.6.4 Sanofi S.A. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.7 Alexion Pharmaceuticals Inc.
16.7.1 Company Profile
16.7.2 Main Business and Rare Disease Drug Information
16.7.3 SWOT Analysis of Alexion Pharmaceuticals Inc.
16.7.4 Alexion Pharmaceuticals Inc. Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.8 Eli Lilly and Company
16.8.1 Company Profile
16.8.2 Main Business and Rare Disease Drug Information
16.8.3 SWOT Analysis of Eli Lilly and Company
16.8.4 Eli Lilly and Company Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.9 Novo Nordisk A/S
16.9.1 Company Profile
16.9.2 Main Business and Rare Disease Drug Information
16.9.3 SWOT Analysis of Novo Nordisk A/S
16.9.4 Novo Nordisk A/S Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)
16.10 AstraZeneca
16.10.1 Company Profile
16.10.2 Main Business and Rare Disease Drug Information
16.10.3 SWOT Analysis of AstraZeneca
16.10.4 AstraZeneca Rare Disease Drug Sales, Revenue, Price and Gross Margin (2016-2021)

For more information about this report visit https://www.researchandmarkets.com/r/ws99cg

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets